EDIT Stock Price | Editas Medicine Inc P/E, Revenue, EPS, & Forecasts

Editas Medicine Inc • EDIT

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Editas Medicine Inc

Ticker

EDIT

Trading on

NASDAQ

ISIN

US28106W1036

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Gilmore O'Neill M.D.

Headquarters

11 Hurley Street, Cambridge, MA, United States, 02141

Employees

246

Website

editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Metrics

BasicAdvanced

Market cap

$204M

P/E ratio

EPS

-$2.35

Dividend Yield

0.00%

Beta

2.16

Forward P/E ratio

EBIDTA

$-112M

Ex dividend date

Price & volume

Market cap

$204M

Average daily volume

1.9M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

4.4

Price to book

15.17

Earnings

EPS

-$2.35

EPS estimate (current quarter)

-$0.38

EPS estimate (next quarter)

-$0.26

EBITDA

$-112M

Revenues (TTM)

$46.4M

Revenues per share (TTM)

$0.55

Technicals

Beta

2.16

52-week High

$4.54

52-week Low

$0.91

50-day moving average

$2.39

200-day moving average

$2.42

Short ratio

6.44

Short %

11.62%

Management effectiveness

ROE (TTM)

-211.37%

ROA (TTM)

-28.26%

Profit margin

0.00%

Gross profit margin

$-64.8M

Operating margin

-325.44%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

12,265.60%

Share stats

Outstanding Shares

97.6M

Float

97.3M

Insiders %

0.27%

Institutions %

47.30%

Analyst Insights & forecasts

34% Buy

53% Hold

13% Sell

Based on information from 15 analysts.

Average price target

$5.13

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.55

-$0.33

-67.38%

Q4 • 24Missed

-$0.92

-$0.66

-39.39%

Q1 • 25Missed

-$0.63

-$0.40

-57.50%

Q2 • 25Missed

-$0.28

-$0.30

6.67%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$3.6M

$-53.2M

-1,487.84%

Q2 • 25

$7.5M

$-25.1M

-332.98%

Q3 • 25

110.82%

-52.82%

-77.62%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$211M

$191M

90.89%

Q2 • 25

$202M

$188M

93.33%

Q3 • 25

-4.19%

-1.62%

2.69%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-50.2M

$42.7M

$7.4M

$-50.2M

Q2 • 25

$-30.8M

$39.6M

$17.2M

$-31.3M

Q3 • 25

-38.57%

-7.21%

131.64%

-37.71%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Editas Medicine Inc share?

Editas Medicine Inc shares are currently traded for undefined per share.

How many shares does Editas Medicine Inc have?

Editas Medicine Inc currently has 97.6M shares.

Does Editas Medicine Inc pay dividends?

No, Editas Medicine Inc doesn't pay dividends.

What is Editas Medicine Inc 52 week high?

Editas Medicine Inc 52 week high is $4.54.

What is Editas Medicine Inc 52 week low?

Editas Medicine Inc 52 week low is $0.91.

What is the 200-day moving average of Editas Medicine Inc?

Editas Medicine Inc 200-day moving average is $2.42.

Who is Editas Medicine Inc CEO?

The CEO of Editas Medicine Inc is Dr. Gilmore O'Neill M.D..

How many employees Editas Medicine Inc has?

Editas Medicine Inc has 246 employees.

What is the market cap of Editas Medicine Inc?

The market cap of Editas Medicine Inc is $204M.

What is the P/E of Editas Medicine Inc?

The current P/E of Editas Medicine Inc is null.

What is the EPS of Editas Medicine Inc?

The EPS of Editas Medicine Inc is -$2.35.

What is the PEG Ratio of Editas Medicine Inc?

The PEG Ratio of Editas Medicine Inc is 0.

What do analysts say about Editas Medicine Inc?

According to the analysts Editas Medicine Inc is considered a hold.